Abstract
Diagnostic tools have not kept pace with medical knowledge. Fields of proteomics, genomics, and bioinformatics have enjoyed explosive growth, but precious few biomarkers found are translated into clinical practice. More than 20,000 scientific-discovery papers for cancer and 6,000 for cardiac disease have been published, yet only about one biomarker per year for ALL diagnostics areas received FDA each year. Unless biomarkers receive FDA approval they cannot move into widespread clinical practice in the US. Rich biomarker data combined with microfabrication techniques can provide means to deploy quick, affordable point-of-care diagnostics. This newfound wealth of information has strong potential to be used to build a “biomarker highway” and develop low-cost, advanced diagnostic tools that identify diseases early including various types of cancers, when they are less costly. This presentation features creation of programmable nano-bio-chip sensors that are capable of sophisticated measurements of strategic biomarkers from bio-fluid samples like blood, urine and saliva. This universal detection modality is now of a fast track to FDA approval through the simultaneous completion of 6 clinical trials in the area of HIV immune function (number one global humanitarian issue), cardiac heart disease (largest killer globally) and three types of cancers (oral, ovarian, prostate). These powerful devices have secured Popular Science Best of What's New (medical device category) as well as Science Coallition's Discovery of Year. The talk will highlight activities related to the recent launching of the Texas Cancer Diagnostics Pipeline.
Short Description: Programmable bio-nano-chip sensors are now in development with goal to diagnose cancer early while at the same time making healthcare more affordable and accessible globally.
Citation Information: Cancer Prev Res 2011;4(10 Suppl):PL01-02.
RSS Feeds